nodes	percent_of_prediction	percent_of_DWPC	metapath
Flavoxate—PDE8B—leg—type 2 diabetes mellitus	0.0337	0.195	CbGeAlD
Flavoxate—PDE8B—hindlimb—type 2 diabetes mellitus	0.0301	0.174	CbGeAlD
Flavoxate—PDE7A—kidney—type 2 diabetes mellitus	0.00903	0.0521	CbGeAlD
Flavoxate—PDE8B—islet of Langerhans—type 2 diabetes mellitus	0.00888	0.0513	CbGeAlD
Flavoxate—PDE8A—islet of Langerhans—type 2 diabetes mellitus	0.00799	0.0461	CbGeAlD
Flavoxate—PDE7B—adipose tissue—type 2 diabetes mellitus	0.00711	0.0411	CbGeAlD
Flavoxate—Eosinophilia—Chlorpropamide—type 2 diabetes mellitus	0.00648	0.0171	CcSEcCtD
Flavoxate—PDE8A—nephron tubule—type 2 diabetes mellitus	0.00643	0.0371	CbGeAlD
Flavoxate—PDE8B—adipose tissue—type 2 diabetes mellitus	0.00566	0.0327	CbGeAlD
Flavoxate—PDE8A—pancreas—type 2 diabetes mellitus	0.00561	0.0324	CbGeAlD
Flavoxate—PDE8A—cortex of kidney—type 2 diabetes mellitus	0.0055	0.0318	CbGeAlD
Flavoxate—PDE8A—adipose tissue—type 2 diabetes mellitus	0.00509	0.0294	CbGeAlD
Flavoxate—PDE4D—cortex of kidney—type 2 diabetes mellitus	0.00499	0.0288	CbGeAlD
Flavoxate—PDE7B—liver—type 2 diabetes mellitus	0.00499	0.0288	CbGeAlD
Flavoxate—PDE4D—adipose tissue—type 2 diabetes mellitus	0.00461	0.0267	CbGeAlD
Flavoxate—Leukopenia—Tolbutamide—type 2 diabetes mellitus	0.00449	0.0119	CcSEcCtD
Flavoxate—Vertigo—Tolazamide—type 2 diabetes mellitus	0.0041	0.0108	CcSEcCtD
Flavoxate—PDE4A—adipose tissue—type 2 diabetes mellitus	0.00408	0.0236	CbGeAlD
Flavoxate—Leukopenia—Tolazamide—type 2 diabetes mellitus	0.00408	0.0108	CcSEcCtD
Flavoxate—Leukopenia—Chlorpropamide—type 2 diabetes mellitus	0.00408	0.0108	CcSEcCtD
Flavoxate—Eosinophilia—Glimepiride—type 2 diabetes mellitus	0.00401	0.0106	CcSEcCtD
Flavoxate—PDE8B—liver—type 2 diabetes mellitus	0.00397	0.0229	CbGeAlD
Flavoxate—Drowsiness—Glipizide—type 2 diabetes mellitus	0.00387	0.0102	CcSEcCtD
Flavoxate—PDE4B—islet of Langerhans—type 2 diabetes mellitus	0.00382	0.0221	CbGeAlD
Flavoxate—Palpitations—Nateglinide—type 2 diabetes mellitus	0.00373	0.00986	CcSEcCtD
Flavoxate—Drowsiness—Glimepiride—type 2 diabetes mellitus	0.00361	0.00954	CcSEcCtD
Flavoxate—Skin disorder—Linagliptin—type 2 diabetes mellitus	0.00358	0.00945	CcSEcCtD
Flavoxate—PDE8A—liver—type 2 diabetes mellitus	0.00357	0.0206	CbGeAlD
Flavoxate—Eosinophilia—Glyburide—type 2 diabetes mellitus	0.00331	0.00874	CcSEcCtD
Flavoxate—Leukopenia—Repaglinide—type 2 diabetes mellitus	0.00327	0.00865	CcSEcCtD
Flavoxate—Drowsiness—Bromocriptine—type 2 diabetes mellitus	0.00326	0.00861	CcSEcCtD
Flavoxate—Urticaria—Tolbutamide—type 2 diabetes mellitus	0.00325	0.00858	CcSEcCtD
Flavoxate—PDE4D—liver—type 2 diabetes mellitus	0.00324	0.0187	CbGeAlD
Flavoxate—Palpitations—Repaglinide—type 2 diabetes mellitus	0.00323	0.00854	CcSEcCtD
Flavoxate—Leukopenia—Rosiglitazone—type 2 diabetes mellitus	0.00309	0.00817	CcSEcCtD
Flavoxate—Feeling abnormal—Tolazamide—type 2 diabetes mellitus	0.00307	0.0081	CcSEcCtD
Flavoxate—Tension—Glipizide—type 2 diabetes mellitus	0.00297	0.00784	CcSEcCtD
Flavoxate—Urticaria—Tolazamide—type 2 diabetes mellitus	0.00296	0.00781	CcSEcCtD
Flavoxate—Urticaria—Chlorpropamide—type 2 diabetes mellitus	0.00296	0.00781	CcSEcCtD
Flavoxate—Nervousness—Glipizide—type 2 diabetes mellitus	0.00294	0.00776	CcSEcCtD
Flavoxate—Urticaria—Linagliptin—type 2 diabetes mellitus	0.00293	0.00773	CcSEcCtD
Flavoxate—Skin disorder—Repaglinide—type 2 diabetes mellitus	0.0029	0.00766	CcSEcCtD
Flavoxate—Vision blurred—Glipizide—type 2 diabetes mellitus	0.00285	0.00753	CcSEcCtD
Flavoxate—Urticaria—Acarbose—type 2 diabetes mellitus	0.00284	0.0075	CcSEcCtD
Flavoxate—Tension—Glimepiride—type 2 diabetes mellitus	0.00277	0.00732	CcSEcCtD
Flavoxate—Tension—Sitagliptin—type 2 diabetes mellitus	0.00276	0.0073	CcSEcCtD
Flavoxate—CHRM2—cardiovascular system—type 2 diabetes mellitus	0.00274	0.0158	CbGeAlD
Flavoxate—Nervousness—Glimepiride—type 2 diabetes mellitus	0.00274	0.00724	CcSEcCtD
Flavoxate—Urticaria—Nateglinide—type 2 diabetes mellitus	0.00274	0.00724	CcSEcCtD
Flavoxate—Nervousness—Sitagliptin—type 2 diabetes mellitus	0.00273	0.00722	CcSEcCtD
Flavoxate—Vertigo—Glipizide—type 2 diabetes mellitus	0.00272	0.00718	CcSEcCtD
Flavoxate—Leukopenia—Glipizide—type 2 diabetes mellitus	0.00271	0.00715	CcSEcCtD
Flavoxate—Nausea—Miglitol—type 2 diabetes mellitus	0.0027	0.00714	CcSEcCtD
Flavoxate—PDE4B—pancreas—type 2 diabetes mellitus	0.00268	0.0155	CbGeAlD
Flavoxate—Drowsiness—Gliclazide—type 2 diabetes mellitus	0.00268	0.00707	CcSEcCtD
Flavoxate—Vision blurred—Glimepiride—type 2 diabetes mellitus	0.00266	0.00703	CcSEcCtD
Flavoxate—Vision blurred—Sitagliptin—type 2 diabetes mellitus	0.00265	0.00701	CcSEcCtD
Flavoxate—PDE4B—cortex of kidney—type 2 diabetes mellitus	0.00263	0.0152	CbGeAlD
Flavoxate—Vertigo—Pioglitazone—type 2 diabetes mellitus	0.0026	0.00688	CcSEcCtD
Flavoxate—Headache—Tolbutamide—type 2 diabetes mellitus	0.00256	0.00677	CcSEcCtD
Flavoxate—Vertigo—Sitagliptin—type 2 diabetes mellitus	0.00253	0.00668	CcSEcCtD
Flavoxate—Leukopenia—Glimepiride—type 2 diabetes mellitus	0.00253	0.00668	CcSEcCtD
Flavoxate—Tension—Bromocriptine—type 2 diabetes mellitus	0.0025	0.0066	CcSEcCtD
Flavoxate—CHRM1—cardiovascular system—type 2 diabetes mellitus	0.0025	0.0144	CbGeAlD
Flavoxate—Palpitations—Glimepiride—type 2 diabetes mellitus	0.00249	0.00659	CcSEcCtD
Flavoxate—Confusional state—Glipizide—type 2 diabetes mellitus	0.00249	0.00658	CcSEcCtD
Flavoxate—Nervousness—Bromocriptine—type 2 diabetes mellitus	0.00247	0.00653	CcSEcCtD
Flavoxate—PDE4B—adipose tissue—type 2 diabetes mellitus	0.00243	0.0141	CbGeAlD
Flavoxate—Nausea—Tolbutamide—type 2 diabetes mellitus	0.00243	0.00642	CcSEcCtD
Flavoxate—Vision blurred—Bromocriptine—type 2 diabetes mellitus	0.0024	0.00634	CcSEcCtD
Flavoxate—Urticaria—Repaglinide—type 2 diabetes mellitus	0.00237	0.00626	CcSEcCtD
Flavoxate—Vomiting—Chlorpropamide—type 2 diabetes mellitus	0.00237	0.00625	CcSEcCtD
Flavoxate—Dry mouth—Glimepiride—type 2 diabetes mellitus	0.00235	0.00621	CcSEcCtD
Flavoxate—Dry mouth—Sitagliptin—type 2 diabetes mellitus	0.00234	0.00619	CcSEcCtD
Flavoxate—Headache—Chlorpropamide—type 2 diabetes mellitus	0.00233	0.00616	CcSEcCtD
Flavoxate—Headache—Tolazamide—type 2 diabetes mellitus	0.00233	0.00616	CcSEcCtD
Flavoxate—Confusional state—Glimepiride—type 2 diabetes mellitus	0.00232	0.00614	CcSEcCtD
Flavoxate—Headache—Linagliptin—type 2 diabetes mellitus	0.00231	0.0061	CcSEcCtD
Flavoxate—Skin disorder—Pioglitazone—type 2 diabetes mellitus	0.0023	0.00607	CcSEcCtD
Flavoxate—Vertigo—Bromocriptine—type 2 diabetes mellitus	0.00229	0.00604	CcSEcCtD
Flavoxate—Vomiting—Acarbose—type 2 diabetes mellitus	0.00227	0.00601	CcSEcCtD
Flavoxate—Tachycardia—Glimepiride—type 2 diabetes mellitus	0.00225	0.00594	CcSEcCtD
Flavoxate—Urticaria—Rosiglitazone—type 2 diabetes mellitus	0.00224	0.00592	CcSEcCtD
Flavoxate—Drowsiness—Metformin—type 2 diabetes mellitus	0.00224	0.00591	CcSEcCtD
Flavoxate—Skin disorder—Sitagliptin—type 2 diabetes mellitus	0.00223	0.00589	CcSEcCtD
Flavoxate—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.00221	0.00584	CcSEcCtD
Flavoxate—Nausea—Tolazamide—type 2 diabetes mellitus	0.00221	0.00584	CcSEcCtD
Flavoxate—Eosinophilia—Losartan—type 2 diabetes mellitus	0.00221	0.00583	CcSEcCtD
Flavoxate—Somnolence—Glipizide—type 2 diabetes mellitus	0.00219	0.0058	CcSEcCtD
Flavoxate—Vision blurred—Glyburide—type 2 diabetes mellitus	0.00219	0.0058	CcSEcCtD
Flavoxate—Vomiting—Nateglinide—type 2 diabetes mellitus	0.00219	0.00579	CcSEcCtD
Flavoxate—Nausea—Acarbose—type 2 diabetes mellitus	0.00212	0.00561	CcSEcCtD
Flavoxate—Dry mouth—Bromocriptine—type 2 diabetes mellitus	0.00212	0.0056	CcSEcCtD
Flavoxate—Confusional state—Bromocriptine—type 2 diabetes mellitus	0.0021	0.00554	CcSEcCtD
Flavoxate—Leukopenia—Glyburide—type 2 diabetes mellitus	0.00208	0.00551	CcSEcCtD
Flavoxate—Tension—Gliclazide—type 2 diabetes mellitus	0.00205	0.00542	CcSEcCtD
Flavoxate—Somnolence—Glimepiride—type 2 diabetes mellitus	0.00205	0.00541	CcSEcCtD
Flavoxate—Nausea—Nateglinide—type 2 diabetes mellitus	0.00205	0.00541	CcSEcCtD
Flavoxate—Somnolence—Sitagliptin—type 2 diabetes mellitus	0.00204	0.00539	CcSEcCtD
Flavoxate—Feeling abnormal—Glipizide—type 2 diabetes mellitus	0.00203	0.00537	CcSEcCtD
Flavoxate—Nervousness—Gliclazide—type 2 diabetes mellitus	0.00203	0.00536	CcSEcCtD
Flavoxate—Tachycardia—Bromocriptine—type 2 diabetes mellitus	0.00203	0.00536	CcSEcCtD
Flavoxate—Skin disorder—Bromocriptine—type 2 diabetes mellitus	0.00202	0.00533	CcSEcCtD
Flavoxate—Urticaria—Glipizide—type 2 diabetes mellitus	0.00196	0.00518	CcSEcCtD
Flavoxate—Feeling abnormal—Pioglitazone—type 2 diabetes mellitus	0.00195	0.00515	CcSEcCtD
Flavoxate—Confusional state—Glyburide—type 2 diabetes mellitus	0.00192	0.00506	CcSEcCtD
Flavoxate—Feeling abnormal—Glimepiride—type 2 diabetes mellitus	0.0019	0.00502	CcSEcCtD
Flavoxate—Vomiting—Repaglinide—type 2 diabetes mellitus	0.0019	0.00501	CcSEcCtD
Flavoxate—Eosinophilia—Ramipril—type 2 diabetes mellitus	0.00189	0.005	CcSEcCtD
Flavoxate—Feeling abnormal—Sitagliptin—type 2 diabetes mellitus	0.00189	0.005	CcSEcCtD
Flavoxate—Urticaria—Pioglitazone—type 2 diabetes mellitus	0.00188	0.00496	CcSEcCtD
Flavoxate—Leukopenia—Gliclazide—type 2 diabetes mellitus	0.00187	0.00494	CcSEcCtD
Flavoxate—Headache—Repaglinide—type 2 diabetes mellitus	0.00187	0.00494	CcSEcCtD
Flavoxate—Somnolence—Bromocriptine—type 2 diabetes mellitus	0.00185	0.00488	CcSEcCtD
Flavoxate—Palpitations—Gliclazide—type 2 diabetes mellitus	0.00185	0.00488	CcSEcCtD
Flavoxate—Urticaria—Glimepiride—type 2 diabetes mellitus	0.00183	0.00484	CcSEcCtD
Flavoxate—Urticaria—Sitagliptin—type 2 diabetes mellitus	0.00182	0.00482	CcSEcCtD
Flavoxate—Vision blurred—Valsartan—type 2 diabetes mellitus	0.00181	0.00478	CcSEcCtD
Flavoxate—Vision blurred—Orlistat—type 2 diabetes mellitus	0.00179	0.00473	CcSEcCtD
Flavoxate—Nausea—Repaglinide—type 2 diabetes mellitus	0.00177	0.00468	CcSEcCtD
Flavoxate—Headache—Rosiglitazone—type 2 diabetes mellitus	0.00177	0.00467	CcSEcCtD
Flavoxate—Dry mouth—Gliclazide—type 2 diabetes mellitus	0.00174	0.0046	CcSEcCtD
Flavoxate—Vertigo—Valsartan—type 2 diabetes mellitus	0.00173	0.00456	CcSEcCtD
Flavoxate—Confusional state—Gliclazide—type 2 diabetes mellitus	0.00172	0.00454	CcSEcCtD
Flavoxate—Feeling abnormal—Bromocriptine—type 2 diabetes mellitus	0.00171	0.00452	CcSEcCtD
Flavoxate—PDE4B—liver—type 2 diabetes mellitus	0.00171	0.00986	CbGeAlD
Flavoxate—Vertigo—Orlistat—type 2 diabetes mellitus	0.00171	0.0045	CcSEcCtD
Flavoxate—Palpitations—Valsartan—type 2 diabetes mellitus	0.0017	0.00448	CcSEcCtD
Flavoxate—Palpitations—Orlistat—type 2 diabetes mellitus	0.00168	0.00443	CcSEcCtD
Flavoxate—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.00168	0.00443	CcSEcCtD
Flavoxate—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.00167	0.0044	CcSEcCtD
Flavoxate—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.00166	0.00438	CcSEcCtD
Flavoxate—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.00165	0.00436	CcSEcCtD
Flavoxate—Vision blurred—Metformin—type 2 diabetes mellitus	0.00165	0.00435	CcSEcCtD
Flavoxate—Antrafenine—PTGS2—type 2 diabetes mellitus	0.00163	0.612	CrCbGaD
Flavoxate—Tension—Irbesartan—type 2 diabetes mellitus	0.00162	0.00428	CcSEcCtD
Flavoxate—Nervousness—Irbesartan—type 2 diabetes mellitus	0.0016	0.00424	CcSEcCtD
Flavoxate—Dry mouth—Valsartan—type 2 diabetes mellitus	0.0016	0.00422	CcSEcCtD
Flavoxate—Dry mouth—Orlistat—type 2 diabetes mellitus	0.00158	0.00417	CcSEcCtD
Flavoxate—Vomiting—Glipizide—type 2 diabetes mellitus	0.00157	0.00415	CcSEcCtD
Flavoxate—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.00157	0.00414	CcSEcCtD
Flavoxate—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.00156	0.00411	CcSEcCtD
Flavoxate—Headache—Glipizide—type 2 diabetes mellitus	0.00155	0.00409	CcSEcCtD
Flavoxate—Palpitations—Metformin—type 2 diabetes mellitus	0.00155	0.00408	CcSEcCtD
Flavoxate—Tension—Losartan—type 2 diabetes mellitus	0.00152	0.00403	CcSEcCtD
Flavoxate—Skin disorder—Valsartan—type 2 diabetes mellitus	0.00152	0.00402	CcSEcCtD
Flavoxate—Somnolence—Gliclazide—type 2 diabetes mellitus	0.00152	0.00401	CcSEcCtD
Flavoxate—Urticaria—Glyburide—type 2 diabetes mellitus	0.00151	0.00399	CcSEcCtD
Flavoxate—Nervousness—Losartan—type 2 diabetes mellitus	0.00151	0.00399	CcSEcCtD
Flavoxate—Skin disorder—Orlistat—type 2 diabetes mellitus	0.0015	0.00397	CcSEcCtD
Flavoxate—Vertigo—Irbesartan—type 2 diabetes mellitus	0.00148	0.00392	CcSEcCtD
Flavoxate—Headache—Pioglitazone—type 2 diabetes mellitus	0.00148	0.00391	CcSEcCtD
Flavoxate—Leukopenia—Irbesartan—type 2 diabetes mellitus	0.00148	0.0039	CcSEcCtD
Flavoxate—Nausea—Glipizide—type 2 diabetes mellitus	0.00147	0.00387	CcSEcCtD
Flavoxate—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00146	0.00387	CcSEcCtD
Flavoxate—Vision blurred—Losartan—type 2 diabetes mellitus	0.00146	0.00387	CcSEcCtD
Flavoxate—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.00146	0.00386	CcSEcCtD
Flavoxate—Headache—Glimepiride—type 2 diabetes mellitus	0.00144	0.00381	CcSEcCtD
Flavoxate—Headache—Sitagliptin—type 2 diabetes mellitus	0.00144	0.0038	CcSEcCtD
Flavoxate—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.00141	0.00371	CcSEcCtD
Flavoxate—Vertigo—Losartan—type 2 diabetes mellitus	0.0014	0.00369	CcSEcCtD
Flavoxate—Somnolence—Valsartan—type 2 diabetes mellitus	0.00139	0.00368	CcSEcCtD
Flavoxate—Leukopenia—Losartan—type 2 diabetes mellitus	0.00139	0.00367	CcSEcCtD
Flavoxate—Skin disorder—Metformin—type 2 diabetes mellitus	0.00139	0.00366	CcSEcCtD
Flavoxate—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.00137	0.00363	CcSEcCtD
Flavoxate—Palpitations—Losartan—type 2 diabetes mellitus	0.00137	0.00363	CcSEcCtD
Flavoxate—Nausea—Glimepiride—type 2 diabetes mellitus	0.00137	0.00362	CcSEcCtD
Flavoxate—Nausea—Sitagliptin—type 2 diabetes mellitus	0.00136	0.0036	CcSEcCtD
Flavoxate—Urticaria—Gliclazide—type 2 diabetes mellitus	0.00136	0.00358	CcSEcCtD
Flavoxate—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.00132	0.00349	CcSEcCtD
Flavoxate—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.00131	0.00347	CcSEcCtD
Flavoxate—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.00131	0.00346	CcSEcCtD
Flavoxate—Tension—Ramipril—type 2 diabetes mellitus	0.00131	0.00345	CcSEcCtD
Flavoxate—Headache—Bromocriptine—type 2 diabetes mellitus	0.0013	0.00344	CcSEcCtD
Flavoxate—Nervousness—Ramipril—type 2 diabetes mellitus	0.00129	0.00342	CcSEcCtD
Flavoxate—Dry mouth—Losartan—type 2 diabetes mellitus	0.00129	0.00342	CcSEcCtD
Flavoxate—Confusional state—Losartan—type 2 diabetes mellitus	0.00128	0.00338	CcSEcCtD
Flavoxate—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.00128	0.00337	CcSEcCtD
Flavoxate—Somnolence—Metformin—type 2 diabetes mellitus	0.00127	0.00335	CcSEcCtD
Flavoxate—Urticaria—Valsartan—type 2 diabetes mellitus	0.00125	0.00329	CcSEcCtD
Flavoxate—Tachycardia—Losartan—type 2 diabetes mellitus	0.00124	0.00327	CcSEcCtD
Flavoxate—Nausea—Bromocriptine—type 2 diabetes mellitus	0.00123	0.00326	CcSEcCtD
Flavoxate—Urticaria—Orlistat—type 2 diabetes mellitus	0.00123	0.00325	CcSEcCtD
Flavoxate—Vomiting—Glyburide—type 2 diabetes mellitus	0.00121	0.00319	CcSEcCtD
Flavoxate—Somnolence—Irbesartan—type 2 diabetes mellitus	0.0012	0.00316	CcSEcCtD
Flavoxate—Vertigo—Ramipril—type 2 diabetes mellitus	0.0012	0.00316	CcSEcCtD
Flavoxate—Leukopenia—Ramipril—type 2 diabetes mellitus	0.00119	0.00315	CcSEcCtD
Flavoxate—Headache—Glyburide—type 2 diabetes mellitus	0.00119	0.00314	CcSEcCtD
Flavoxate—Palpitations—Ramipril—type 2 diabetes mellitus	0.00118	0.00311	CcSEcCtD
Flavoxate—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.00118	0.00311	CcSEcCtD
Flavoxate—Urticaria—Metformin—type 2 diabetes mellitus	0.00113	0.003	CcSEcCtD
Flavoxate—Nausea—Glyburide—type 2 diabetes mellitus	0.00113	0.00298	CcSEcCtD
Flavoxate—Somnolence—Losartan—type 2 diabetes mellitus	0.00113	0.00298	CcSEcCtD
Flavoxate—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.00111	0.00293	CcSEcCtD
Flavoxate—Dry mouth—Ramipril—type 2 diabetes mellitus	0.00111	0.00293	CcSEcCtD
Flavoxate—Confusional state—Ramipril—type 2 diabetes mellitus	0.0011	0.0029	CcSEcCtD
Flavoxate—Vomiting—Gliclazide—type 2 diabetes mellitus	0.00108	0.00287	CcSEcCtD
Flavoxate—Urticaria—Irbesartan—type 2 diabetes mellitus	0.00107	0.00283	CcSEcCtD
Flavoxate—Headache—Gliclazide—type 2 diabetes mellitus	0.00107	0.00282	CcSEcCtD
Flavoxate—Tachycardia—Ramipril—type 2 diabetes mellitus	0.00106	0.0028	CcSEcCtD
Flavoxate—Skin disorder—Ramipril—type 2 diabetes mellitus	0.00106	0.00279	CcSEcCtD
Flavoxate—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.00104	0.00276	CcSEcCtD
Flavoxate—Raloxifene—CYP3A4—type 2 diabetes mellitus	0.00103	0.388	CrCbGaD
Flavoxate—Nausea—Gliclazide—type 2 diabetes mellitus	0.00101	0.00268	CcSEcCtD
Flavoxate—Urticaria—Losartan—type 2 diabetes mellitus	0.00101	0.00266	CcSEcCtD
Flavoxate—Vomiting—Valsartan—type 2 diabetes mellitus	0.000997	0.00263	CcSEcCtD
Flavoxate—Vomiting—Orlistat—type 2 diabetes mellitus	0.000985	0.0026	CcSEcCtD
Flavoxate—Headache—Valsartan—type 2 diabetes mellitus	0.000982	0.00259	CcSEcCtD
Flavoxate—Headache—Orlistat—type 2 diabetes mellitus	0.00097	0.00256	CcSEcCtD
Flavoxate—Somnolence—Ramipril—type 2 diabetes mellitus	0.000966	0.00255	CcSEcCtD
Flavoxate—Nausea—Valsartan—type 2 diabetes mellitus	0.000931	0.00246	CcSEcCtD
Flavoxate—Nausea—Orlistat—type 2 diabetes mellitus	0.00092	0.00243	CcSEcCtD
Flavoxate—Vomiting—Metformin—type 2 diabetes mellitus	0.000908	0.0024	CcSEcCtD
Flavoxate—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.000896	0.00237	CcSEcCtD
Flavoxate—Headache—Metformin—type 2 diabetes mellitus	0.000894	0.00236	CcSEcCtD
Flavoxate—Urticaria—Ramipril—type 2 diabetes mellitus	0.000864	0.00228	CcSEcCtD
Flavoxate—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000857	0.00226	CcSEcCtD
Flavoxate—Nausea—Metformin—type 2 diabetes mellitus	0.000848	0.00224	CcSEcCtD
Flavoxate—Headache—Irbesartan—type 2 diabetes mellitus	0.000844	0.00223	CcSEcCtD
Flavoxate—Vomiting—Losartan—type 2 diabetes mellitus	0.000806	0.00213	CcSEcCtD
Flavoxate—Nausea—Irbesartan—type 2 diabetes mellitus	0.0008	0.00211	CcSEcCtD
Flavoxate—Headache—Losartan—type 2 diabetes mellitus	0.000794	0.0021	CcSEcCtD
Flavoxate—Nausea—Losartan—type 2 diabetes mellitus	0.000753	0.00199	CcSEcCtD
Flavoxate—Vomiting—Ramipril—type 2 diabetes mellitus	0.000691	0.00183	CcSEcCtD
Flavoxate—Headache—Ramipril—type 2 diabetes mellitus	0.000681	0.0018	CcSEcCtD
Flavoxate—Nausea—Ramipril—type 2 diabetes mellitus	0.000646	0.00171	CcSEcCtD
Flavoxate—PDE4D—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.42e-05	7.67e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	3.41e-05	7.65e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.4e-05	7.64e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—RBP4—type 2 diabetes mellitus	3.39e-05	7.61e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—GLP1R—type 2 diabetes mellitus	3.39e-05	7.61e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—AVP—type 2 diabetes mellitus	3.38e-05	7.59e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—MMP3—type 2 diabetes mellitus	3.38e-05	7.59e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCKAR—type 2 diabetes mellitus	3.38e-05	7.58e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—INS—type 2 diabetes mellitus	3.37e-05	7.55e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	3.36e-05	7.55e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—RELA—type 2 diabetes mellitus	3.35e-05	7.52e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCKAR—type 2 diabetes mellitus	3.34e-05	7.48e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.31e-05	7.43e-05	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—IL6—type 2 diabetes mellitus	3.29e-05	7.38e-05	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—IL6—type 2 diabetes mellitus	3.29e-05	7.38e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—EDN1—type 2 diabetes mellitus	3.26e-05	7.31e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.26e-05	7.31e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.25e-05	7.3e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.25e-05	7.3e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.25e-05	7.29e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.24e-05	7.27e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—EDN1—type 2 diabetes mellitus	3.22e-05	7.22e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	3.21e-05	7.2e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	3.17e-05	7.11e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—C3—type 2 diabetes mellitus	3.14e-05	7.03e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—INS—type 2 diabetes mellitus	3.11e-05	6.99e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.1e-05	6.96e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.1e-05	6.96e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	3.1e-05	6.95e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—C3—type 2 diabetes mellitus	3.09e-05	6.94e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.09e-05	6.94e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.06e-05	6.88e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	3.06e-05	6.87e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	3.06e-05	6.86e-05	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.05e-05	6.85e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IAPP—type 2 diabetes mellitus	3.04e-05	6.83e-05	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.03e-05	6.8e-05	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.03e-05	6.8e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.02e-05	6.79e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—INSR—type 2 diabetes mellitus	3.02e-05	6.78e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	3.02e-05	6.78e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.01e-05	6.76e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.01e-05	6.75e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—IL6—type 2 diabetes mellitus	3e-05	6.74e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IAPP—type 2 diabetes mellitus	3e-05	6.74e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3e-05	6.73e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—INSR—type 2 diabetes mellitus	2.98e-05	6.7e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—AGT—type 2 diabetes mellitus	2.98e-05	6.68e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TRPC6—type 2 diabetes mellitus	2.97e-05	6.66e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	2.97e-05	6.66e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AGTR2—type 2 diabetes mellitus	2.95e-05	6.63e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.95e-05	6.62e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.95e-05	6.62e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—AGT—type 2 diabetes mellitus	2.94e-05	6.6e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TRPC6—type 2 diabetes mellitus	2.93e-05	6.58e-05	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—IL6—type 2 diabetes mellitus	2.93e-05	6.57e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	2.93e-05	6.57e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—RELA—type 2 diabetes mellitus	2.92e-05	6.55e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AGTR2—type 2 diabetes mellitus	2.92e-05	6.54e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CCR5—type 2 diabetes mellitus	2.91e-05	6.54e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CCR5—type 2 diabetes mellitus	2.88e-05	6.45e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.86e-05	6.42e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.86e-05	6.41e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—C3—type 2 diabetes mellitus	2.85e-05	6.39e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—EDNRB—type 2 diabetes mellitus	2.83e-05	6.35e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.83e-05	6.34e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—C3—type 2 diabetes mellitus	2.81e-05	6.31e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—EDNRB—type 2 diabetes mellitus	2.79e-05	6.26e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—RELA—type 2 diabetes mellitus	2.78e-05	6.23e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.77e-05	6.22e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	2.75e-05	6.18e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PSMD6—type 2 diabetes mellitus	2.75e-05	6.16e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HTR2C—type 2 diabetes mellitus	2.75e-05	6.16e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.73e-05	6.13e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.73e-05	6.13e-05	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.72e-05	6.11e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	2.72e-05	6.1e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PSMD6—type 2 diabetes mellitus	2.71e-05	6.08e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HTR2C—type 2 diabetes mellitus	2.71e-05	6.08e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—AGT—type 2 diabetes mellitus	2.71e-05	6.07e-05	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.7e-05	6.06e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	2.67e-05	5.99e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—AGT—type 2 diabetes mellitus	2.67e-05	5.99e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	2.66e-05	5.97e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CYBA—type 2 diabetes mellitus	2.66e-05	5.97e-05	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.66e-05	5.96e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—EDNRA—type 2 diabetes mellitus	2.64e-05	5.92e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—SRC—type 2 diabetes mellitus	2.63e-05	5.91e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.63e-05	5.91e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CALM1—type 2 diabetes mellitus	2.63e-05	5.89e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CYBA—type 2 diabetes mellitus	2.62e-05	5.89e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.62e-05	5.87e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	2.61e-05	5.86e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—GHRL—type 2 diabetes mellitus	2.6e-05	5.84e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PLAT—type 2 diabetes mellitus	2.6e-05	5.84e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	2.58e-05	5.79e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CALCA—type 2 diabetes mellitus	2.57e-05	5.77e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—RELA—type 2 diabetes mellitus	2.57e-05	5.77e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PLAT—type 2 diabetes mellitus	2.57e-05	5.76e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—GHRL—type 2 diabetes mellitus	2.57e-05	5.76e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.57e-05	5.76e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CALCA—type 2 diabetes mellitus	2.54e-05	5.69e-05	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.53e-05	5.68e-05	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.51e-05	5.64e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.51e-05	5.62e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	2.5e-05	5.61e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.49e-05	5.59e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.49e-05	5.58e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	2.47e-05	5.54e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.46e-05	5.52e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	2.42e-05	5.43e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.41e-05	5.41e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	2.41e-05	5.41e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	2.39e-05	5.36e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—GCG—type 2 diabetes mellitus	2.38e-05	5.34e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	2.38e-05	5.34e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	2.38e-05	5.34e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.37e-05	5.31e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.36e-05	5.29e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—GCG—type 2 diabetes mellitus	2.35e-05	5.27e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PTPN1—type 2 diabetes mellitus	2.35e-05	5.27e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.34e-05	5.26e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	2.34e-05	5.25e-05	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.34e-05	5.25e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	2.33e-05	5.24e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.32e-05	5.2e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	2.31e-05	5.19e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.31e-05	5.18e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	2.3e-05	5.17e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.3e-05	5.17e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.3e-05	5.15e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—SRC—type 2 diabetes mellitus	2.29e-05	5.15e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.23e-05	5.01e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	2.23e-05	5e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CCL2—type 2 diabetes mellitus	2.2e-05	4.93e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.19e-05	4.92e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	2.19e-05	4.91e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	2.19e-05	4.91e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—SRC—type 2 diabetes mellitus	2.18e-05	4.9e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.17e-05	4.86e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—AKT2—type 2 diabetes mellitus	2.16e-05	4.85e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	2.16e-05	4.84e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.13e-05	4.77e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.13e-05	4.77e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	2.07e-05	4.65e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—GNB3—type 2 diabetes mellitus	2.05e-05	4.6e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.05e-05	4.6e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	2.04e-05	4.59e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—GNB3—type 2 diabetes mellitus	2.03e-05	4.54e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AVP—type 2 diabetes mellitus	2.02e-05	4.54e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MMP3—type 2 diabetes mellitus	2.02e-05	4.54e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—SRC—type 2 diabetes mellitus	2.02e-05	4.53e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IGF2—type 2 diabetes mellitus	2.02e-05	4.52e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.01e-05	4.51e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	2.01e-05	4.5e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AVP—type 2 diabetes mellitus	2e-05	4.48e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MMP3—type 2 diabetes mellitus	2e-05	4.48e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.99e-05	4.46e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.99e-05	4.46e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.98e-05	4.44e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.97e-05	4.42e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.96e-05	4.4e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—APOB—type 2 diabetes mellitus	1.96e-05	4.39e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.95e-05	4.38e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.95e-05	4.37e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—APOB—type 2 diabetes mellitus	1.93e-05	4.33e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.93e-05	4.32e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.92e-05	4.32e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.91e-05	4.29e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.9e-05	4.26e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—LPL—type 2 diabetes mellitus	1.87e-05	4.19e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—LPL—type 2 diabetes mellitus	1.84e-05	4.14e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.83e-05	4.1e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.81e-05	4.05e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.81e-05	4.05e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—IL6—type 2 diabetes mellitus	1.77e-05	3.98e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.77e-05	3.97e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.75e-05	3.93e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.73e-05	3.88e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.72e-05	3.86e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.7e-05	3.81e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—C3—type 2 diabetes mellitus	1.68e-05	3.77e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—C3—type 2 diabetes mellitus	1.66e-05	3.73e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.64e-05	3.67e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.6e-05	3.6e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.6e-05	3.59e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AGT—type 2 diabetes mellitus	1.6e-05	3.59e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.58e-05	3.55e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.58e-05	3.54e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AGT—type 2 diabetes mellitus	1.58e-05	3.54e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.57e-05	3.53e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—APOE—type 2 diabetes mellitus	1.57e-05	3.51e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—LEP—type 2 diabetes mellitus	1.57e-05	3.51e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.55e-05	3.48e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.55e-05	3.47e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—LEP—type 2 diabetes mellitus	1.55e-05	3.47e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—APOE—type 2 diabetes mellitus	1.55e-05	3.47e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—IL6—type 2 diabetes mellitus	1.55e-05	3.47e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.53e-05	3.43e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.48e-05	3.31e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.47e-05	3.3e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.46e-05	3.27e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.43e-05	3.2e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.4e-05	3.13e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.38e-05	3.09e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—IL6—type 2 diabetes mellitus	1.36e-05	3.05e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.36e-05	3.04e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—INS—type 2 diabetes mellitus	1.34e-05	3e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—INS—type 2 diabetes mellitus	1.32e-05	2.96e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.32e-05	2.95e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.3e-05	2.92e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.29e-05	2.9e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.29e-05	2.9e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.29e-05	2.89e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.28e-05	2.87e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.28e-05	2.86e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.27e-05	2.85e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.26e-05	2.82e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.23e-05	2.76e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.21e-05	2.72e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.17e-05	2.63e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.17e-05	2.63e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.16e-05	2.6e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.16e-05	2.6e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.1e-05	2.48e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.09e-05	2.45e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.01e-05	2.26e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.96e-06	2.23e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	9.92e-06	2.23e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.89e-06	2.22e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.83e-06	2.21e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.77e-06	2.19e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.41e-06	2.11e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.31e-06	2.09e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.29e-06	2.08e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.19e-06	2.06e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.13e-06	2.05e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.01e-06	2.02e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	8.68e-06	1.95e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SRC—type 2 diabetes mellitus	8.57e-06	1.92e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.45e-06	1.9e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.34e-06	1.87e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.76e-06	1.74e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.66e-06	1.72e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.61e-06	1.71e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.51e-06	1.68e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	5.84e-06	1.31e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IL6—type 2 diabetes mellitus	5.77e-06	1.29e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.39e-06	1.21e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.32e-06	1.19e-05	CbGpPWpGaD
